NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 198 filers reported holding NOVOCURE LTD in Q2 2019. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $565,250 | -75.8% | 35,000 | -37.7% | 0.01% | -78.6% |
| Q2 2023 | $2,332,342 | -88.3% | 56,201 | -83.0% | 0.04% | -89.1% |
| Q1 2023 | $19,932,381 | +19.3% | 331,433 | +45.5% | 0.39% | +47.9% |
| Q4 2022 | $16,709,130 | +62.5% | 227,800 | +68.4% | 0.26% | +83.8% |
| Q3 2022 | $10,280,000 | +66.6% | 135,300 | +52.4% | 0.14% | +67.1% |
| Q2 2022 | $6,172,000 | +49.0% | 88,800 | +77.6% | 0.08% | +70.0% |
| Q1 2022 | $4,142,000 | -77.5% | 50,000 | -79.6% | 0.05% | -75.8% |
| Q4 2021 | $18,435,000 | -36.1% | 245,494 | -1.2% | 0.21% | -37.3% |
| Q3 2021 | $28,868,000 | -19.4% | 248,500 | +54.0% | 0.33% | -29.5% |
| Q2 2021 | $35,802,000 | +160.5% | 161,400 | +55.2% | 0.47% | +58.1% |
| Q1 2021 | $13,746,000 | -72.3% | 104,000 | -63.7% | 0.30% | -73.8% |
| Q4 2020 | $49,576,000 | +2021.4% | 286,500 | +1264.3% | 1.13% | +1956.4% |
| Q3 2020 | $2,337,000 | -32.8% | 21,000 | -61.8% | 0.06% | -68.6% |
| Q2 2019 | $3,477,000 | – | 55,000 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |